Takeda Finishes Construction of Manufacturing Facility in Germany

Takeda inaugurated expanded capacity of solid-dosage drugs at its site in Oranienburg, Germany.

Takeda Pharmaceutical Company has completed the construction of new manufacturing facilities at its site in Oranienburg, Germany, the company announced on June 16, 2017. The new, 21,400-m2 production facility was built at a total cost of around 100 million euros and is scheduled to begin operating at the end of 2017. The state of Brandenburg and the German federal government each contributed half of the approximately 23 million euros in subsidies for the plant expansion.

In a press release issued November 27, 2014, Takeda announced that, as a part of its initiative toward optimization of its global network, the manufacture of solid dosage form pharmaceutical products would be transferred from the Osaka Plant to the Oranienburg Plant and the Hikari Plant. The completion of this new manufacturing facility in Germany is an integral part of this effort.

Specialized in producing solid forms (pills and capsules), the Oranienburg site, which has a 130-year history of pharmaceutical production in Germany, plays a key role in Takeda’s global manufacturing network. Many of Takeda’s drug products are manufactured and supplied to 100 countries worldwide from the Oranienburg site. The expanded production capacity of the Oranienburg site will make it possible to meet the increased demand for Takeda’s products in global markets, including rapidly growing emerging markets, and has already created about 180 new jobs.

Source: Takeda